{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.0","upperLimit":"13.6","value":"9.9"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.7","upperLimit":"18.3","value":"14.2"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"13.9","value":"10.2"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"352"}],"units":"Participants"}],"description":"This was a key secondary endpoint in this study and included patients in the EEP with rhPSMA-7.3 (18F) imaging.","dispersionType":"95% Confidence Interval","groups":[{"description":"all patients who received rhPSMA-7.3 (18F) injection followed by a PET scan. This population included M0 and M1 patients independent of performance of RP and PLND and was used for M1 related efficacy and Kappa statistics.","id":"OG000","title":"Extended Efficacy Population (EEP)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET. followed by treatment within 60 days post IMP administration","title":"Verified Detection Rate (VDR) for M1 Lesions - Percentage of Patients in Whom rhPSMA-7.3 (18F) Imaging Detected at Least One Verified M1 Metastasis, as Determined by Central BIE and Confirmed by SoT (Biopsy or Imaging) (Objective 1)","type":"SECONDARY","unitOfMeasure":"percentage"}